Tumor heterogeneity and drug resistance
- PMID: 3944607
- DOI: 10.1200/JCO.1986.4.2.244
Tumor heterogeneity and drug resistance
Abstract
Drug resistance has long been identified as a major reason for therapy failure in cancer patients. Concurrently, work from many laboratories in the past 10 years has established tumor heterogeneity as a phenomenon of critical importance in the natural history of individual neoplasms. The two most sinister aspects of intraneoplastic diversity in human solid tumors are the genesis of clones with metastatic potential, and the existence of drug-resistant variants in primary cancers and their metastases. Thus, recent investigations on drug resistance and on tumor heterogeneity have converged to focus attention on the clonal organization of primary tumors and their metastases as the underlying basis for anticancer drug resistance. This review examines the degree of heterogeneity observed within tumors and the relationship of this diversity to resistance that might be anticipated for any given agent. A question critical to our discussion is "How many subpopulations are there?" The impact of multiple tumor clones on therapy is next discussed in relationship to normal tissue tolerance, the barrier clinicians face regardless of the specific agent used in treatment. Finally, laboratory and clinical approaches are presented for addressing a drug resistance problem that is seemingly overwhelming because of its complex biological roots.
Similar articles
-
Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.Cancer Treat Rep. 1986 Jan;70(1):183-99. Cancer Treat Rep. 1986. PMID: 3510734 Review.
-
On the genesis and regulation of cellular heterogeneity in malignant tumors.Invasion Metastasis. 1982;2(3):137-76. Invasion Metastasis. 1982. PMID: 6765249 Review.
-
Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases.Cancer Res. 1984 Sep;44(9):3801-5. Cancer Res. 1984. PMID: 6744297
-
Quantitative genetic analysis of tumor progression.Cancer Metastasis Rev. 1985;4(2):173-92. doi: 10.1007/BF00050694. Cancer Metastasis Rev. 1985. PMID: 3893685 Review.
-
The Ernst W. Bertner Memorial Award lecture: the evolution of biological heterogeneity in metastatic neoplasms.Symp Fundam Cancer Res. 1983;36:5-26. Symp Fundam Cancer Res. 1983. PMID: 6382521 Review.
Cited by
-
Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer.Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1833-8. doi: 10.1073/pnas.1414653112. Epub 2015 Jan 26. Proc Natl Acad Sci U S A. 2015. PMID: 25624490 Free PMC article.
-
Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients.Front Oncol. 2016 Mar 29;6:72. doi: 10.3389/fonc.2016.00072. eCollection 2016. Front Oncol. 2016. PMID: 27066454 Free PMC article.
-
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).Cancer Metastasis Rev. 1988 Dec;7(4):335-45. doi: 10.1007/BF00051374. Cancer Metastasis Rev. 1988. PMID: 3061677 Review.
-
Integration of quantitative methods and mathematical approaches for the modeling of cancer cell proliferation dynamics.Am J Physiol Cell Physiol. 2023 Feb 1;324(2):C247-C262. doi: 10.1152/ajpcell.00185.2022. Epub 2022 Dec 12. Am J Physiol Cell Physiol. 2023. PMID: 36503241 Free PMC article. Review.
-
Cancer immunoediting of the NK group 2D ligand H60a.J Immunol. 2011 Oct 1;187(7):3538-45. doi: 10.4049/jimmunol.1100413. Epub 2011 Aug 29. J Immunol. 2011. PMID: 21876033 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
